Does a high thyroid-stimulating hormone (TSH) level affect pregnancy?

Elevated thyroid-stimulating hormone (TSH) levels—particularly when above the pregnancy-specific reference range—can significantly impact fertility and pregnancy outcomes. During conception and early pregnancy, optimal thyroid function is critical because the developing embryo relies entirely on maternal thyroid hormone until approximately 10–12 weeks’ gestation, when fetal thyroid gland development begins. Untreated or inadequately treated subclinical or overt hypothyroidism (often reflected by elevated TSH) is associated with increased risks of infertility, miscarriage, preterm birth, placental abruption, gestational hypertension, and impaired neurocognitive development in the offspring.

Current guidelines from the American Thyroid Association (ATA) recommend that TSH be maintained below 2.5 mIU/L in the first trimester and below 3.0 mIU/L in the second and third trimesters for women with known thyroid disease or positive thyroid peroxidase (TPO) antibodies. For women undergoing fertility treatment or attempting conception, TSH should ideally be optimized to ≤2.5 mIU/L prior to conception. Levothyroxine is the standard treatment; dosage adjustments are often required during pregnancy due to increased thyroid hormone demand, and TSH should be monitored every 4 weeks during the first half of pregnancy.

Importantly, isolated mild TSH elevation without detectable thyroid antibodies or abnormal free thyroxine (fT4) may carry lower risk—but still warrants evaluation and individualized management. All women with a history of thyroid dysfunction, autoimmune disease, prior miscarriage, or infertility should undergo thyroid function testing—including TSH and TPO antibodies—before conception or early in pregnancy.